🇺🇸 FDA
Patent

US 11629349

RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

granted A61KA61K31/713

Quick answer

US patent 11629349 (RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use) held by Arrowhead Pharmaceuticals, Inc. expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/713